Drug Profile
Latanoprost emulsion - Santen SAS
Alternative Names: Catioprost; DE 130A; Nova21027; SNTN-10130; STN-1013001; STN10130Latest Information Update: 23 Nov 2023
Price :
$50
*
At a glance
- Originator Novagali Pharma
- Developer Santen Pharmaceutical; Santen S.A.S.
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Glaucoma; Ocular hypertension
Most Recent Events
- 22 Nov 2023 CHMP recommends positive opinion of Latanoprost emulsion for in open-angle glaucoma and ocular hypertension in European Union (Santen Pharmaceutical pipeline, November 2023)
- 06 Oct 2022 Preregistration for Glaucoma in European Union (Ophthalmic)
- 06 Oct 2022 Preregistration for Ocular hypertension in European Union (Ophthalmic)